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Abstract 
In breast cancer radiation has a central role in the treatment of brain metastasis, even 
though tumor sensitivity might be limited. The tumor cell defense response to ionizing 
radiation involves activation of cell cycle checkpoint signaling. Histone deacetylase 
(HDAC) inhibitors, agents that cause hyperacetylation of histone proteins and thereby 
aberrations in the chromatin structure, may also override the DNA damage defense 
response and facilitate the radiation-induced mitotic cell death. In experimental 
metastasis models, the human breast carcinoma cell line MA-11 invariably 
disseminates to the central nervous system. We compared in vitro MA-11 cell cycle 
response profiles to ionizing radiation and HDAC inhibition. After radiation exposure 
the G2/M phase accumulation and the preceding repression of the G2 phase regulatory 
factors Polo-like kinase-1 and cyclin B1 required intact G2 checkpoint signaling 
through the checkpoint kinase CHK1, whereas the similar phenotypic changes 
observed upon HDAC inhibition did not. The MA-11 cells did not show radiation-
induced expression of the G1 cell cycle inhibitor p21, indicative of a defective G1 
checkpoint and consistent with a point mutation detected in the tumor-suppressor 
TP53 gene. Increase in the p21 level, however, was observed upon HDAC inhibition. 
Following pretreatment with the HDAC inhibitor, the efficiency of clonogenic 
regrowth after irradiation was reduced, which is in accordance with the concept of 
increased probability of mitotic cell death when the chromatin structure is disrupted. 
Among molecular cell cycle-targeted drugs currently in the pipeline for testing in 




In breast cancer radiation as therapeutic modality has clearly documented palliation 
effect on advanced metastatic disease in the brain or meninges. Within this patient 
population, however, survival may vary from a few months to a couple of years. 
Hence, improvement of the standard therapy might potentially benefit many patients 
(1). 
We have previously characterized the MA-11 human breast carcinoma cell 
line for its ability to form experimental organ-specific metastases in vivo. This cell 
line was established from micrometastatic cells enriched from a bone marrow sample 
taken from a patient who was clinically devoid of metastatic disease (2), but was 
somewhat unexpectedly found to form metastases within the central nervous system 
after systemic injection in rodents (2–4). This experimental metastasis model has been 
characterized for therapeutic responses to a variety of pharmacological compounds 
with cytotoxic activity (3, 5). 
Cell cycle checkpoints constitute regulatory mechanisms that do not allow the 
initiation of a new phase of the cell cycle to proceed before the previous one is 
completed (6). The tumor cell response to DNA damage involves a temporary cell 
cycle delay at the G1/S or G2/M boundaries, each based on unique mechanisms, to 
activate a cascade of responses to the damage, ultimately leading to the outcome of 
cell survival if the DNA is properly repaired, or, if not, to apoptotic or mitotic cell 
death (7). 
The tumor-suppressor protein p53 is the primary regulator of the G1 
checkpoint (7). Essentially, in tumor cells with intact p53 function, DNA damage 
leads to rapid p53 stabilization by post-translational protein modifications as well as 
induction in the level of the G1 phase inhibitor p21 (7). 
 4
In the orderly dividing cell the transition from the G2 phase to mitosis is 
inhibited through phosphorylations of the Cdc2 kinase of the Cdc2/cyclin B complex. 
Upon the onset of mitosis these inhibitory phosphorylations are removed by the 
Cdc25C phosphatase. The activation of Cdc25C requires positive regulatory 
phosphorylation, accomplished by the Polo-like kinase-1 (Plk1) (8). DNA damage-
induced G2 checkpoint signaling, initiated by the ATM kinase and communicated 
through downstream mediator proteins like p53 and the checkpoint kinase CHK1 (6, 
9), will ultimately disrupt the interaction of Cdc25C with Cdc2 (6). We have 
previously found that the mechanism of the G2 phase response to ionizing radiation 
comprises repression of the genes for Plk1 and cyclin B1, PLK and CCNB1 (10). 
Molecular targeted agents can have direct effects on the cellular response 
pathways implicated upon exposure to ionizing radiation (11). A variety of 
pharmacological compounds, designed to target cell cycle regulatory mechanisms, 
have been shown to override the DNA damage defense response that prevents mitotic 
entry (9, 11). Hence, such agents may have a therapeutic potential as radiosensitizers 
by facilitating mitotic cell death, and several are currently tested in early-phase 
clinical trials. We have recently reported that pharmacological inhibition of the CHK1 
kinase counteracted the tumor cell defense responses on PLK and CCNB1, and 
thereby the G2 arrest, following radiation exposure (10, 12). In agreement with this, 
the concomitant treatment with the CHK1 inhibitor seemed to amplify the cytotoxic 
effect of ionizing radiation on clonogenic regrowth (12). 
Drugs that modify the cellular chromatin structure may also radiosensitize 
tumor cells. Taxanes, which disrupt chromatin structure and chromosome segregation 
in mitotis, are currently utilized clinically as radiosensitizers in treatment of non-small 
cell lung cancer and head-and-neck cancer (13). Cellular treatment with histone 
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deacetylase (HDAC) inhibitors causes hyperacetylation of histone proteins, which 
leads to aberration in the chromatin structure (14). In addition to this, the pertubation 
by HDAC inhibitors of cell cycle checkpoint signaling (15), might constitute the 
cellular mechanism by which these compounds enhance tumor cell sensitivity to 
radiation treatment. 
Currently several HDAC inhibitors are undergoing early-phase clinical 
investigation (14). Such pipeline drugs are not easily accessible, and in this report we 
have used a commercially available HDAC inhibitor, trichostatin A (TSA). TSA has 
shown excessive toxicity under in vivo conditions, and in this study we have therefore 
compared the biological mechanisms involved in the responses of the MA-11 cell 
cycle phenotype after exposure to TSA and ionizing radiation in cultured cells. A 
reduction in MA-11 clonogenic regrowth by the concomitant treatment with TSA and 
radiation is further indicated. 
 
Materials and Methods 
Cell Lines and Experimental Treatments 
 The human carcinoma cell lines MA-11 and MT-1 were cultured as previously 
described (4). High-energy radiation from a 60Co source was delivered at a rate of 
approximately 1 Gy/min. The unirradiated control cells were simultaneously placed in 
room temperature to obtain exactly comparable conditions. The commercially 
available HDAC inhibitor TSA (Sigma-Aldrich Norway, Oslo, Norway) was added to 
the media in final concentrations of 10–300 nM. In experiments using the selective 
CHK1 kinase inhibitor UCN-01 (National Cancer Institute, Bethesda, MD), this 
compound was added in a final concentration of 100 nM to the cell media, as 
recommended by the supplier, 15 minutes before irradiation or TSA treatment. 
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Western Blot Analysis 
 Protein expression was measured by means of standard Western blot 
technique, essentially as previously described (10). The membranes were stained with 
amidoblack to evaluate equal protein loading, and subsequently hybridized with 
designated primary antibodies obtained from Upstate (Lake Placid, NY), 
Calbiochem/Merck Biosciences Ltd. (Nottingham, UK), Santa Cruz Biotechnology 
(Santa Cruz, CA), Chemicon International (Temecula, CA), or Zymed Laboratories 
Inc. (San Francisco, CA). These were anti-acetyl-histone H4 (Upstate; 06-866), anti-
α-tubulin (Calbiochem; CP06), anti-poly(ADP-ribose) polymerase-1 (anti-PARP) 
(Calbiochem; 512739), anti-p53 (SC-6243), anti-MDM2 (Chemicon; MAB4134), 
anti-Plk1 (Zymed; 33-1700), and anti-p21 (SC-6246), respectively. 
Flow Cytometry Analysis 
The MA-11 cells were harvested in ice-cold PBS, and after centrifugation the 
cell pellets were fixed in 100% methanol. To determine the fractions of cells in the 
G1, S, and G2/M phases from the cell cycle distribution, the cells were stained with 1.5 
µg/ml Hoechst 33258 in PBS and analyzed in a FACStar+ flow cytometer (Becton 
Dickinson, San Jose, CA), as described previously (10). 
Mutation Analysis of the TP53 Gene 
 DNA extracted from the cell lines was analyzed for possible TP53 mutations 
using the method of constant denaturant gel electrophoresis (CDGE) (16). The 
screening was performed using PCR to amplify exons 2, 3, and 6−11 individually, as 
well as the large exons 4 and 5 each as two sequential PCR products (17). The sample 
that showed aberrantly migrating bands, indicating mutation, was reamplified using 
the original set of primers, of which one was biotinylated, and the same thermal 
cycling condition. The biotinylated PCR product was sequenced directly by means of 
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the standard dideoxy method and Dynabeads M280−Streptavidin (Dynal, Oslo, 
Norway) as solid support. 
Northern Blot Analysis 
Expression of RNA was measured by means of standard Northern blot 
technique, as described previously (10). The human cDNA probe for TP53 was 
provided by Dr. B. Smith-Sørensen (The Norwegian Radium Hospital, Oslo, 
Norway), whereas the human cDNA clones for PLK and CCNB1 were obtained from 
RZPD Deutsches Ressourcenzentrum für Genomforschung GmbH (Berlin, Germany). 
The human cDNA probe for CDKN1A was a gift from Dr. B. Vogelstein (The John 
Hopkins University School of Medicine, Baltimore, MD). To evaluate the amounts of 
RNA loaded, the filters were rehybridized to a kinase-labeled oligonucleotide probe 
complementary to nucleotides 287-305 of human 18S rRNA. 
Assessment of Clonogenic Regrowth 
Clonogenic regrowth efficiency of the MA-11 cell line was determined by 
plating single cells suspended in media with or without TSA (10–300 nM) for 12 
hours, before the media were replaced with fresh media and the cells irradiated. The 
appropriate plating density was aimed to produce 20–40 surviving colonies in each 
well of 6-well culture plates, and the mean plating efficiency of the control MA-11 
cells was not more than ∼0.225 in the three independent sets of experiments. After 
incubation for 2–3 weeks, the cells were fixed and stained with 0.1% crystal violet. 
Colonies of ≥50 cells were counted for computing of the surviving fraction. At least 
four parallel samples were scored in the three repetitions performed for each treatment 
condition. 
Calculation of Radiation-TSA Interactions 
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The results from the clonogenic regrowth measurements were analyzed using 
the combination index (CI) method of Chou and Talalay (18). CI values <0.90 are 
indicative of synergistic interactions, whereas additive interactions are indicated by CI 
values of 0.90–1.0 and antagonistic interactions by CI values >1.1. 
 
Results 
HDAC Inhibition ― Histone Acetylation and PARP Protein Status 
 Tumor cell sensitivity to pharmacological HDAC inhibition may vary along a 
wide concentration range and should be considered highly cell line specific. Thus, the 
initial experiment was performed to determine the effect of increasing concentrations 
of TSA (10–300 nM) on the histone acetylation status of the MA-11 cell line. As seen 
from Fig. 1, upper panel, the level of acetylated histone H4 was significantly induced 
after 6−12 hours exposure to the higher TSA concentrations (100 and 300 nM) before 
the level again dropped below detection after 24 hours. In contrast, histone H4 
acetylation was not seen in cells treated with TSA in the lower concentration range 
(10 and 30 nM). The expression pattern of acetylated histone H3 was closely identical 
(data not shown), which might indicate that MA-11 cell histones are insensitive to 
TSA below a threshold concentration. 
These data suggested that TSA in a concentration of 300 nM might be 
appropriate for further mechanistic studies. The possibility of MA-11 cell apoptosis 
by this high TSA concentration (19, 20) was analyzed by means of PARP cleavage as 
we have recently demonstrated that degradation of this nuclear repair enzyme is a 
sensitive indicator of apoptotic cell death activated by a Pseudomonas exotoxin A-
containing immunotoxin in the MA-11 cells (21). In contrast to what was detected in 
the immunotoxin-treated cells, the PARP protein remained intact in MA-11 cells 
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incubated with 300 nM TSA throughout the observation period of 24 hours (Fig. 1, 
lower panel), excluding apoptosis as an essential mechanism in TSA-induced MA-11 
cell death (see below). 
Ionizing Radiation and HDAC Inhibition ― Redistribution of Cell Cycle 
Phases 
Pharmacological inhibition of HDAC activity has been shown to cause cell 
cycle arrest at the G2/M boundary in a variety of tumor cell lines (19, 20, 22–24), 
resembling the G2 checkpoint response to DNA damage induced by ionizing radiation 
(10, 12, 25). Hence, the MA-11 cells were exposed to a radiation dose of 8.0 Gy or 
300 nM TSA, and cell cycle profiles were followed for 24 hours (Fig. 2, upper panel). 
The irradiated cells displayed an apparent accumulation of G2/M phase cells 
throughout the observation period. The fraction of G2/M phase cells increased from 
20−25% of the total cell counts after 12 hours to ~40% after 24 hours. A similar 
redistribution of cell cycle phases was observed in the TSA-treated cells, although a 
larger cell fraction was in S phase and a significantly lower fraction (~30% of the total 
cell counts) was arrested in the G2/M phase after 24 hours, compared to cells exposed 
to ionizing radiation. 
p53 Status 
In the MA-11 cells a distinct G1 phase was detected following both irradiation 
and TSA treatment (Fig. 2). The persisting G1 phase cells may reflect an incomplete 
G2/M phase arrest, allowing DNA-damaged cells to pass into the G1 phase of a new 
cell cycle. Alternatively, the regulatory mechanism of such pattern of cell cycle 
redistribution may involve a functional G1 checkpoint. Hence, the cellular p53 status 
was analyzed and compared with that of the MT-1 cell line, in which cell cycle 
responses to ionizing radiation have been reported previously (10, 12). 
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As depicted by Fig. 3, upper panel, CDGE analysis of DNA from the MA-11 
cell line revealed aberrant migration of a PCR fragment representing exon 5 of the 
TP53 gene, in accordance with the base substitution of C for a T nucleotide in codon 
126, resulting in change of amino acid Tyr to His, detected by the subsequent 
sequencing of the PCR fragment. In contrast, we found with DNA from the MT-1 
cells all exons of the TP53 gene to be wildtype upon CDGE analysis. 
Furthermore, both cell lines showed essentially equal levels of mRNA 
expression for TP53 (Fig. 3, middle panel). However, whereas strong p53 protein 
expression was found in the MA-11 cell line, in accordance with the intense nuclear 
staining of p53 previously detected by immunocytochemistry (2), p53 expression was 
almost undetectable in the MT-1 cell extracts. A weak band representing the p53 
protein was seen after long-term exposure of the immunoblot (Fig. 3, lower panel). 
Primarily, p53 stabilization results from disruption of the interaction between 
p53 and the MDM2 oncoprotein, which thereby protects p53 from ubiquitin-mediated 
degradation (26). Whereas expression of two major MDM2 polypeptides was 
observed in the MT-1 cells, MDM2 was almost undetectable in the MA-11 cells (Fig. 
3, lower panel). 
Ionizing Radiation and HDAC Inhibition ― Responses of Cell Cycle 
Regulatory Proteins 
The responses of regulatory proteins of the G1 and G2 cell cycle phases were 
followed for 24 hours after MA-11 cell exposure to ionizing radiation (8.0 Gy) or 
TSA (300 nM). As seen from Fig. 4, expression of the G2 phase kinase Plk1 was 
found to be down-regulated 6 hours after irradiation, with an apparent increase above 
the control Plk1 level, probably compensatory, after12−24 hours. This has also been 
observed in irradiated MT-1 cells (12). A transient Plk1 repression was also seen 
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6−12 hours after start of the TSA treatment but almost recovered after 24 hours. From 
below detection, the level of the G1 phase inhibitor p21 was induced 12 hours after 
addition of TSA and further observed as clearly accumulating after 24 hours. 
Coincident with this, the high level of p53 was significantly repressed. In contrast to 
the TSA-dependent effects on p21 and p53, the expression levels of these proteins 
were not altered by radiation. 
The regulatory responses on cell cycle proteins seemed to reflect changes in 
mRNA levels after exposure of the MA-11 cells to ionizing radiation or TSA (Fig. 5). 
As previously observed in other breast cancer cell lines (10, 12, 25), the level of PLK 
mRNA (encoding Plk1) was barely detectable 6 hours after irradiation but almost 
recovered after 12 hours, and the response of CCNB1 mRNA (encoding the G2 phase-
specific cyclin B1) was essentially identical. The transient down-regulation of these 
mRNAs by TSA was observed for some longer period (6−12 hours) before their 
expression again was up-regulated 24 hours after start of the TSA treatment. The 
mRNA expression of CDKN1A (encoding p21) was not altered after irradiation, 
which is highly indicative of a defective G1 checkpoint (7). In the presence of TSA, 
however, expression of CDKN1A mRNA was inversely reflecting the regulatory 
effects on the mRNAs for PLK and CCNB1. 
Ionizing Radiation and HDAC Inhibition ― Regulatory Role of CHK1 
We have recently shown that the cell cycle phenotype responses following 
radiation-induced DNA damage require intact G2 checkpoint signaling through the 
downstream checkpoint kinase CHK1 (10, 12). In accordance with this, treatment 
with the CHK1 inhibitor UCN-01 (100 nM) also seemed to counteract the G2/M phase 
arrest observed 12−24 hours after exposure of the MA-11 cells to a radiation dose of 
8.0 Gy, but not upon incubation with TSA (300 nM) for 24 hours, as seen by 
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comparing the histograms displayed by the upper and lower panels of Fig. 2. 
Furthermore, whereas the suppressed mRNA levels of PLK and CCNB1 following 
irradiation of the MA-11 cells were entirely abolished by UCN-01, the regulatory 
effects of TSA on those mRNAs, and on CDKN1A mRNA, were not (Fig. 5). Hence, 
our data strongly indicate that the effector mechanisms of the G2 phase responses to 
ionizing radiation and HDAC inhibition are mediated via distinct regulatory 
pathways. 
Ionizing Radiation and HDAC Inhibition ― Clonogenic Regrowth 
Finally, the MA-11 cell line was exposed to increasing doses of ionizing 
radiation to determine clonogenic survival (Fig. 6). The cell line showed nearly 
exponential loss of colony formation efficiency, with a surviving fraction of ~0.01 
with the highest radiation dose applied (10 Gy). 
Since the regulatory pathway recruited by HDAC inhibition seemed to be 
distinctly different from that following irradiation, the possible radiosensitizing effect 
of TSA, essentially by amplifying the cytotoxic effect of ionizing radiation on 
clonogenic regrowth, was measured. Based on the histone acetylation data (Fig. 1, 
upper panel), we chose to analyze MA-11 cells treated with TSA (10–300 nM) for 12 
hours before the HDAC inhibitor was removed and the cells irradiated. This treatment 
strategy was supported by the observations that irradiation followed by the immediate 
TSA treatment for 12 hours did not reduce MA-11 cell clonogenicity compared to 
irradiation alone and that TSA incubations for 24 hours or more before or after 
radiation exposure turned out to induce complete cytotoxicity in this cell line (results 
not shown). 
The effects of the TSA pretreatment on several radiation doses were measured 
(Fig. 6) and analyzed by means of the CI method (Table 1). In most of the dose range 
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analyzed (0.50–5.0 Gy) the ability of clonogenic regrowth of irradiated MA-11 cells 
was reduced by a factor of ≤3 after pretreatment with 300 nM TSA. The cytotoxic 
effect of 8.0 Gy of ionizing radiation on clonogenicity (surviving fraction of ~0.04), 
however, was ∼10-fold amplified by TSA (Fig. 6). Moreover, as depicted by Table 1, 
synergistic effects (CI values <0.90) on MA-11 colony formation were found for most 
combinations of TSA and ionizing radiation tested, but, interestingly, TSA in the 
lower concentration range (10 and 30 nM) seemed to antagonize the cytotoxic effect 
of the 5.0 Gy radiation dose on the MA-11 cells. 
 
Discussion 
In this report we have compared cell cycle responses of the human breast carcinoma 
MA-11 cell line to ionizing radiation and HDAC inhibition. Whereas accumulation of 
G2/M phase cells, as well as the preceding repression of the genes encoding the G2 
phase regulators Plk1 and cyclin B1, after irradiation required intact G2 checkpoint 
signaling through the checkpoint kinase CHK1, the similar phenotypic changes 
observed upon HDAC inhibition did not. The MA-11 cells did not show radiation-
dependent induction of the G1 phase inhibitor p21, indicative of a defective G1 
checkpoint and possibly consistent with the base substitution detected in the tumor-
suppressor TP53 gene. Induction in the p21 level, however, was observed upon 
HDAC inhibition. Following pretreatment with the HDAC inhibitor, the efficiency of 
clonogenic regrowth after irradiation was reduced, which is in accordance with the 
concept of increased probability of mitotic cell death when the chromatin structure is 
disrupted. 
 Recent reports have shown that HDAC inhibitors by themselves possess 
antiproliferative effects in a variety of tumor cell lines (19, 20, 24). Moreover, some 
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potential of HDAC inhibitors to sensitize tumor cells to the DNA-damaging 
cytotoxicity of chemotherapeutics and ionizing radiation has lately been observed 
(27–32). Interestingly, in animal models the treatment with HDAC inhibitors 
significantly suppressed cutaneous side effects of radiation therapy (33), suggesting 
that the contemporary approach of molecularly targeted therapy may be utilized to 
increase the therapeutic ratio between the tumor and surrounding normal tissues in 
radiation therapy. 
The clonogenic survival data clearly indicated that TSA in a wide 
concentration range may sensitize the MA-11 cells to the cytotoxic effect of ionizing 
radiation, even though a threshold concentration of the HDAC inhibitor seemed to be 
necessary to obtain histone acetylation, as measured by the expression of acetylated 
histones H4 and H3. It has been shown that TSA also acts via mechanisms involving 
hyperacetylation of non-histone proteins (22). Even though TSA seemed to cause 
acetylation of histones and non-histone proteins within the same concentration range, 
accumulation of acetylated non-histone proteins occurred more rapidly. This 
difference in TSA responses might be of consequence for its cellular toxicity (22) and 
perhaps account for the apparent antagonism observed by low concentrations of TSA 
in the MA-11 cells exposed to 5.0 Gy of ionizing radiation as well. 
Pharmacological inhibition of HDAC activity has previously been shown to 
cause redistribution of cell cycle profiles resembling the G2 checkpoint response to 
DNA damage induced by ionizing radiation (19, 20, 22–24). PLK and CCNB1 are 
among several genes, encoding mitotic regulators, of which the mRNA expression 
levels are down-regulated following activation of the G2 checkpoint (34). The present 
report is the first on TSA-directed down-regulation of PLK mRNA. Whether this is 
regulated at the level of transcription inhibition, similar to what has been shown for 
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the repressed CCNB1 promoter activity upon HDAC inhibition (23, 35, 36), remains 
to be determined. 
The promoter of the human PLK contains a characteristic repressor element in 
the region of the transcription start site, mediating the cell cycle phase-specific 
regulation of the gene expression (37). This repressor element is involved in the 
inhibition of PLK transcription after activation of p21 (38), which can function as a 
highly specific transcriptional regulator of numerous genes involved in cell cycle 
progression and DNA repair (39). However, the observation that PLK mRNA 
repression by TSA clearly preceded the induction of p21, argues against a p21-
directed pathway as the principal effector mechanism. 
Treatment with HDAC inhibitors induces p21 expression by a transcriptional 
mechanism, possibly mediated by the ATM kinase signaling pathway (40) and 
associated changes in the acetylation status of the CDKN1A promoter (23, 41). 
Accordingly, we found both CDKN1A mRNA and the p21 protein induced from very 
low baseline levels after addition of TSA. However, the effector mechanism of this 
p21 accumulation, supposed being initiated by ATM, did not seem to involve the 
downstream checkpoint kinase CHK1, which suggests diversity in the regulatory 
pathways governed by ATM in DNA damage checkpoint control. Similarly, our data 
on repression of Plk1 and cyclin B1 followed by G2/M phase arrest after exposure to 
ionizing radiation and TSA strongly indicate that these G2 phase responses, even if 
they are phenotypically similar, are mediated via distinct regulatory pathways. 
In the MA-11 cells a distinct G1 phase was detected following both irradiation 
and TSA treatment. The regulatory mechanism of such pattern of cell cycle 
redistribution might involve a functional G1 checkpoint, in the event of which a 
radiation-induced up-regulation of CDKN1A mRNA should be observed (7). 
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However, the complete lack of such a response supports the assumption that the 
persisting G1 phase instead reflects an incomplete G2 phase arrest. 
Consistent with a defective G1 checkpoint, a base substitution in codon 126 of 
the TP53 gene and a correspondingly high p53 protein level were detected in the MA-
11 cell line. Primarily, p53 stabilization results from disruption of the interaction 
between p53 and the MDM2 oncoprotein, which thereby protects p53 from ubiquitin-
mediated degradation (26). The expression of MDM2 was almost undetectable in the 
MA-11 cells. This is in accordance with the concept that tumor cells with high 
intrinsic levels of mutant, inactive p53 are unable to induce expression of the MDM2 
protein, which would normally provide a feedback mechanism of p53 destabilization 
in the absence of DNA-damaging events (42). 
Based upon the frequency of recorded TP53 mutations (43), base substitutions 
in codon 126 are rare, but a few examples of missense mutations are reported, e.g., in 
head-and-neck cancer (44, 45) and metastatic lesions from prostate cancer (46). 
Basically, this report describes proof-of-principle experiments on how to use 
HDAC inhibitors to decrease the probability of clonogenic regrowth of tumor cells 
exposed to ionizing radiation. Although appealing as concept, caution must be shown 
upon interpretation and, indeed, possible therapeutic utilization. There are currently 
several HDAC inhibitors in early-phase clinical trials (14). It is reasonable to believe 
that therapeutic indications for these agents primarily will be in combination with 
conventional cytotoxic therapies. 
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Table 1.   CI values for ionizing radiation (IR) plus TSA 
 
IR (Gy) TSA (nM)  CI 
 
2.0  10   0.67 
2.0  30   0.67 
2.0  100   0.51 
2.0  300   0.51 
5.0  10   1.2 
5.0  30   1.1 
5.0  100   0.88 
5.0  300   0.73 
8.0  10   0.78 
8.0  30   0.77 
8.0  100   0.43 




Figure 1.   HDAC inhibition by TSA in MA-11 cells ― histone acetylation and 
PARP protein status. The cells were treated with TSA, either in increasing 
concentrations (upper panel) or in a concentration of 300 nM (+), or left untreated (–) 
(lower panel). Protein extracts prepared after 6–24 hours of incubation were analyzed 
by Western blot hybridization with an antibody against acetylated histone H4 (acetyl-
H4) or an anti-PARP antibody that binds with higher affinity to the PARP cleavage 
fragment (85 kDa) than to the uncleaved fragment (116 kDa). The lower panel also 
includes a protein extract from MA-11 cells treated (+) with 10 ng/ml of a 
Pseudomonas exotoxin A-containing immunotoxin (IT), used as positive control for 
PARP cleavage (21). Expression of α-tubulin was measured as loading control. 
 
Figure 2.   MA-11 cell cycle profiles upon exposure to ionizing radiation (IR) or the 
HDAC inhibitor TSA. The cells were treated (+) with IR (8.0 Gy) or TSA (300 nM), 
or left untreated (–), in the absence (upper panel) or presence (lower panel) of the 
CHK1 inhibitor UCN-01 (100 nM), and further incubated for 12 and 24 hours before 
cellular DNA contents were determined by flow cytometry analysis gated for Hoechst 
33258 fluorescence. Scales indicating cell counts (y axes) for G1 and G2 /M phase 
cells, represented by the peaks labeled 2N and 4N, respectively, are provided. 
 
Figure 3.   p53 status of the MA-11 cells, as compared to that of the MT-1 cell line. 
Upper panel, exons 2−11 of the TP53 gene were individually amplified by PCR from 
DNA extracted from the cell lines, and further analyzed by CDGE methodology. Any 
aberrantly migrating PCR fragments were subsequently sequenced. A detected single-
 25
base mutation is indicated. wt, wildtype. Middle panel, TP53 mRNA expression by 
the cell lines was analyzed by Northern blot hybridization, using 18S rRNA as RNA 
loading control. Lower panel, protein expression of p53 and MDM2 was determined 
by Western blot hybridization. 
 
Figure 4.   Checkpoint regulatory proteins in MA-11 cells after exposure to ionizing 
radiation (IR) or the HDAC inhibitor TSA. The cells were treated (+) with IR (8.0 
Gy) or TSA (300 nM), or left untreated (–), and protein expression levels of Plk1, 
p21, p53, and acetylated histone H4 (acetyl-H4) after 0–24 hours were determined by 
Western blot analysis of cell extracts. Expression of α-tubulin was measured as 
loading control. 
 
Figure 5.   Cell cycle regulatory factors and CHK1 signaling after exposure of MA-11 
cells to ionizing radiation (IR) or the HDAC inhibitor TSA. The cells were treated (+) 
with IR (8.0 Gy) or TSA (300 nM), or left untreated (–), in the absence (–) or 
presence (+) of the CHK1 inhibitor UCN-01 (100 nM). Expression levels of mRNAs 
for PLK, CCNB1, and CDKN1A after 0–24 hours were analyzed by Northern blot 
hybridization. 18S rRNA was measured as RNA loading control. 
 
Figure 6.   Inhibition of HDAC activity modulates the outcome of MA-11 clonogenic 
regrowth upon exposure to ionizing radiation. The MA-11 cells were exposed to 
increasing doses of ionizing radiation without (•) or following (o) pretreatment for 12 
hours with TSA (300 nM), to determine relative colony formation compared to the 
unirradiated situation (mean ± SEM, n = 3). 
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